APELLIS PHARMACEUTICALS, INC.
At today's price, APELLIS PHARMACEUTICALS, INC. (APLS) is priced for +37.6% growth. boothcheck doesn't publish a fair value or a price target; it shows what the price assumes, so you can judge whether that bar is too high. Built from SEC EDGAR filings.
• Apellis sells two complement-system drugs, SYFOVRE for the eye disease geographic atrophy and EMPAVELI for rare blood and kidney disorders, and total revenue rose to $268.3 million in the most recent quarter from $166.8 million a year earlier. [Source: Q1 2026 10-Q, May 7 2026] • The defining risk is competition in geographic atrophy, where Astellas' IZERVAY is the direct rival to SYFOVRE and recently won an FDA label update that lets it dose beyond twelve months. [Source: FDA label update, 20
Is APLS overvalued? See what's priced in →
308 institutional managers reported holding APLS in 13F filings for the quarter ended 2026-03-31. 114 opened new positions that quarter. Held by BlackRock, Vanguard Group, Morgan Stanley, among others.
Quarterly 13F filings arrive up to 45 days after quarter end, so the picture is never current (filed through 2026-05-29). Nothing here is investment advice.
APLS's share count grew 57.1% over the past five years. It pays no dividend.
Share counts are split-adjusted; repurchase totals are gross of share issuance. Nothing here is investment advice.
No open-market insider buys on file at APLS over the trailing three years. Absence is a fact about the company, not a signal. 21 officers and directors are on file.
Code P open-market purchases from SEC Form 4 filings, non-derivative, excluding scheduled 10b5-1 plans. Nothing here is investment advice.
APLS's recent reports: the day-one move, then what the following quarter actually did.
| report | day one | next quarter |
|---|---|---|
| 2021-02-26 | -7.9% | +5.2% |
| 2021-08-10 | -3.7% | -43.8% |
| 2022-03-01 | -6.1% | -0.3% |
| 2022-08-09 | +3.8% | -10.6% |
Day-one is the close-to-close move around the filing. Nothing here is investment advice.
Last analyzed: June 27, 2026
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.